Halozyme Therapeutics, Inc. vs. Moderna, Inc. Common Stock
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| HALO | MRNA | |
|---|---|---|
| Market Cap | $12.47 billion | $75.86 billion |
| Revenue (TTM) | $1.66 billion | — |
| Net Income (TTM) | $413.60 million | — |
MRNA leads on 1 of 1 size & scale factors.
Valuation
| HALO | MRNA | |
|---|---|---|
| P/E Ratio | 32.12 | — |
| Price / Book | 86.87 | — |
| Price / Sales | 7.49 | — |
HALO and MRNA split the valuation factors evenly.
Profitability
| HALO | MRNA | |
|---|---|---|
| Net Margin | 24.86% | — |
| Return on Equity | 288.13% | — |
HALO and MRNA split the profitability factors evenly.
Risk & Sentiment
| HALO | MRNA | |
|---|---|---|
| Short Interest | 9.79% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.